727 related articles for article (PubMed ID: 22284968)
1. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
2. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
[TBL] [Abstract][Full Text] [Related]
3. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.
Reinert T; Modin C; Castano FM; Lamy P; Wojdacz TK; Hansen LL; Wiuf C; Borre M; Dyrskjøt L; Orntoft TF
Clin Cancer Res; 2011 Sep; 17(17):5582-92. PubMed ID: 21788354
[TBL] [Abstract][Full Text] [Related]
5. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
6. Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.
Beukers W; Kandimalla R; Masius RG; Vermeij M; Kranse R; van Leenders GJ; Zwarthoff EC
Mod Pathol; 2015 Apr; 28(4):515-22. PubMed ID: 25394776
[TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
8. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.
Retz M; Rotering J; Nawroth R; Buchner A; Stöckle M; Gschwend JE; Lehmann J
Eur Urol; 2011 Aug; 60(2):231-8. PubMed ID: 21190793
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours.
Agundez M; Grau L; Palou J; Algaba F; Villavicencio H; Sanchez-Carbayo M
Eur Urol; 2011 Jul; 60(1):131-40. PubMed ID: 21514719
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
[TBL] [Abstract][Full Text] [Related]
13. Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages.
Descotes F; Dessen P; Bringuier PP; Decaussin M; Martin PM; Adams M; Villers A; Lechevallier E; Rebillard X; Rodriguez-Lafrasse C; Devonec M; Paparel P; Perrin P; Lazar V; Ruffion A
BJU Int; 2014 Feb; 113(2):333-42. PubMed ID: 24053469
[TBL] [Abstract][Full Text] [Related]
14. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.
Shimizu T; Suzuki H; Nojima M; Kitamura H; Yamamoto E; Maruyama R; Ashida M; Hatahira T; Kai M; Masumori N; Tokino T; Imai K; Tsukamoto T; Toyota M
Eur Urol; 2013 Jun; 63(6):1091-100. PubMed ID: 23200812
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
17. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
19. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
